- cafead   Jan 20, 2021 at 11:03: AM
via A drug that Pfizer passed over but saw a revitalized cancer R&D-focused GlaxoSmithKline jump on for $4.2 billion has come up as a dud in a key trial pitting it against U.S. Merck’s blockbuster Keytruda. That drug, originally known as M7824, now bintrafusp alfa, works as a bifunctional fusion protein immunotherapy.
article source
article source